Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome

NCT03053271 is registered in ClinicalTrials.gov with Millendo Therapeutics US, Inc. as lead sponsor.

NCT NCT03053271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03053271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Lead sponsor
Millendo Therapeutics US, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 13, 2017
Completion date
August 12, 2019
Enrollment
4 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cushing syndrome